Sector News

Thermo Fisher to acquire FEI

June 3, 2016
Life sciences

Thermo Fisher Scientific is slated to buy electron microscope maker FEI Company for $4.2 billion, the firms announced last week (May 27). According to The New York Times, the aquisition is expected to close by early 2017.

“Fundamentally, this transaction bolsters our already strong position in the marketplace and allows us to play an increasing role in enabling our customers to accelerate breakthrough discoveries, increase productivity, and provide solutions to global challenges,” FEI’s Don Kania, president and chief executive officer, said in a statement.

“In life sciences, there is growing adoption of electron microscopy to study the structure of proteins,” Marc Casper, Thermo Fisher chief executive officer, said in a statement. “The technologies we gain with FEI will complement our mass spectrometry leadership, putting Thermo Fisher in the best position to capitalize on this important trend.”

Just two months ago, Casper’s company closed another large acquisition deal: Thermo Fisher bought Affymetrix for $1.3 billion.

By Tracy Vence

Source: The Scientist

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend